CA-KONG-INC.
Kong Inc., the cloud connectivity company, today announced the general availability release of Kong Konnect , a service connectivity platform that enables the modern connected business. First previewed at Kong Summit 2020 in private beta , Kong Konnect provides end users with instant access to a comprehensive suite of tools that enable reliable, secure and observable connectivity across their APIs and microservices. The GA release features new multi-geo support, allowing users to physically locate services close to their businesses for privacy and regulatory compliance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005311/en/
The fully modular platform enables developers, architects and operators to accelerate application development cycles and provide connectivity between services for stellar digital experiences. Architects decouple connectivity concerns from microservices so that developers can focus on building applications instead of wasting time building pipes; developers gain architectural freedom to choose the best language, protocol and cloud services for building their microservices; and operators deploy APIs consistently across any infrastructure to support the hybrid or multi-cloud deployment patterns that the business requires for performance, cost, privacy or regulatory compliance reasons.
With the GA release, Kong is introducing a flexible consumption-based pricing model that brings enterprise-class tech within reach of individual developers as well as large teams. Usage of Kong Konnect is metered, enabling users to pay solely for the number of services used.
Kong Konnect is available in three plan tiers:
- Kong Konnect Free allows developers to instantly try out the product without having to go through an enterprise sales representative.
- Kong Konnect Plus offers a freemium model with a pay-as-you-go, credit card-based option that provides a simple way for developers or operators on small teams to quickly start using the services they need right now.
- Kong Konnect Enterprise is for organizations that want to use the platform as a whole; it provides connectivity with enterprise-grade security, scalability and observability across any cloud, platform and protocol to help teams build powerful digital services and experiences.
“Kong Konnect addresses a massive challenge companies face as they enter digital transformation 2.0, which is characterized by an exponential increase in the volume and variety of connections that need to be activated and secured with lightning-fast speed,” said Marco Palladino, CTO and co-founder of Kong Inc. “One day, we will look back in amazement to realize that developers were spending a lot of time building the plumbing, and writing the networking and security code for each service on each platform. Automated cloud connectivity is inevitable – from gateway to service mesh across every cloud, Kubernetes and VMs – and market-leading companies already know this and are offloading this function so that their top talent can focus on application design and feature development so they can continue to outpace the competition.”
A Service Connectivity Platform That Offers Connections for Everyone
With a modular approach, end users can access capabilities delivered as functional modules and provision different types of runtimes on-demand without requiring purchase of the entire platform. Users are able to select and consume only the features they need directly through the Kong Konnect interface, removing barriers to building next-generation applications and services.
Kong Konnect provides reliable, secure and observable connectivity for services across any infrastructure. The SaaS-based management plane accelerates deployments and provides access to functionality modules, including the Kong ServiceHub , Kong Vitals , Kong Runtime Manager and the Kong Developer Portal . Kong Immunity and Insomnia continue to be available for self-management to customers. The runtimes – Kong Gateway and Kong Mesh – are self-managed and provide the flexibility to support any hybrid or multi-cloud deployment pattern.
To get started with Kong Konnect, please visit https://konghq.com/kong-konnect/ .
About Kong Inc.
Kong creates software and managed services that connect APIs and microservices natively across and within clouds, Kubernetes, data centers and more using intelligent automation. Built on an open source core, Kong’s service connectivity platform enables digital innovation by allowing organizations to reliably and securely manage the full lifecycle of APIs and services for modern architectures, including microservices, serverless and service mesh. By providing developer teams with unprecedented architectural freedom, Kong accelerates innovation cycles, increases productivity, and seamlessly bridges legacy and modern systems and applications. For more information about Kong, please visit konghq.com or follow @thekonginc on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005311/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom